Jump to content
Powered by

Boehringer Ingelheim to acquire US biotech company

Biotech company to fill Boehringer Ingelheim’s pipeline for respiratory diseases: Boehringer Ingelheim has announced an agreement to acquire Actimis Pharmaceuticals, a privately owned biotech company based in San Diego, for 515 million US dollars (approximately 330 million euros).

With this acquisition, Boehringer Ingelheim is specifically targeting an asthma compound developed by Actimis, a spin-off from Bayer. The asthma compound is currently in the first phase of clinical development and has been shown to have a more effective mechanism of action across multiple animal models compared to currently marketed products.

For the first time in its company history, Boehringer Ingelheim will acquire a biotech company. Last year, it was Merck KGaA in Darmstadt that took over the Swiss biotech company Serono.

On 17th June, Boehringer Ingelheim disclosed the information that it will acquire shares of the privately owned US company depending on the achievement of several successive milestones with Actimis’ leading asthma compound AP768. If AP768 is successfully advanced in a phase III, Boehringer Ingelheim will own 100 per cent of Actimis’ shares. Additional details regarding the transaction were not disclosed.

Reinforcement for respiratory disease indication

Andreas Barner: Actimis acquisition strengthens Boehringer Ingelheim's product pipeline. (Photo: Boehringer Ingelheim)
Actimis’ compound provides an innovative addition to Boehringer Ingelheim’s portfolio of development candidates for the potential treatment of respiratory diseases,” says Andreas Barner, Vice-Chairman of the Board Corporate Division Pharma Research, as quoted in the company press release. In 2007, Boehringer Ingelheim achieved a turnover of approximately 1.8 billion euros with Spiriva®, the company’s leading drug for the treatment of respiratory disease.

Actimis is focused exclusively on the research and development of small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases. Actimis was spun off from Bayer Healthcare AG in November 2004.

Source:
Boehringer Ingelheim, Actimis Pharmaceuticals (17th June 2008, wp, (P))
Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-to-acquire-us-biotech-company